OptiMedica Corp. has announced it has closed a $35 million growth round of financing, according to a news release.
The funds will be used, in part, to continue the commercialization of the company's Catalys precision laser system for cataract surgery. It will also go to support the development of system enhancements and the development of a portfolio of additional products.
"OptiMedica has been committed to bringing the precision and safety benefits of femtosecond laser technology to cataract surgery since our founding in 2004. Today, we are literally standing at the forefront of a landscape shift in the field that, we believe, will ultimately make the laser the centerpiece of the procedure," said Mark J. Forchette, OptiMedica president and CEO, in the release. "Catalys has been shown in both clinical practice and clinical studies to deliver unparalleled precision and performance, with results and customer satisfaction that lead the industry. Our exceptional laser technology has enabled surgeons to achieve consistently excellent clinical results and explore a broad new area of innovation in the field. We are actively engaged in this exploration and look forward to a long future of scientific leadership that will continue to bring untold benefits to cataract surgeons and their patients."
Catalys is U.S. FDA market cleared and CE mark approved for performing the laser cataract procedure. It had its U.S. launch in February.
OptiMedica Corp. is headquartered in Sunnydale, Calif.
Related Articles on Ophthalmology:
How Does Revenue Compare for 10 Surgery Center Specialties? 40 Statistics
Ophthalmologists Drs. Edward Isbey and Robert Wiggins Receive AAO Achievement Award
Bascom Palmer to Establish Orbital Vision Research Center